Anti-VEGF agents have revolutionized the field of treatment possibilities and visual prognosis in AMD, offering benefits in terms of improved visual acuity and becoming the gold-standard therapy for CNV [141, 142]. The gene discussed is VEGFA; the disease is age-related macular degeneration.